Northwest Biotherapeutics, Inc. (NWBO)
0.1517
0.00 (0.00%)
USD |
OTCM |
Oct 23, 16:00
Northwest Biotherapeutics Enterprise Value : 326.13M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 326.13M |
| October 22, 2026 | 324.96M |
| October 21, 2026 | 354.51M |
| October 20, 2026 | 347.50M |
| October 19, 2026 | 331.86M |
| October 16, 2026 | 334.14M |
| October 15, 2026 | 331.24M |
| October 14, 2026 | 339.99M |
| October 13, 2026 | 344.14M |
| October 12, 2026 | 343.33M |
| October 09, 2026 | 334.98M |
| October 08, 2026 | 319.96M |
| October 07, 2026 | 320.79M |
| October 06, 2026 | 316.62M |
| October 05, 2026 | 321.29M |
| October 02, 2026 | 329.47M |
| October 01, 2026 | 327.30M |
| September 30, 2026 | 321.46M |
| September 29, 2026 | 322.46M |
| September 28, 2026 | 327.47M |
| September 25, 2026 | 339.99M |
| September 24, 2026 | 339.32M |
| September 23, 2026 | 339.40M |
| September 22, 2026 | 344.99M |
| September 21, 2026 | 351.67M |
| Date | Value |
|---|---|
| September 18, 2026 | 340.15M |
| September 17, 2026 | 349.17M |
| September 16, 2026 | 349.32M |
| September 15, 2026 | 360.19M |
| September 14, 2026 | 348.00M |
| September 11, 2026 | 354.84M |
| September 10, 2026 | 348.75M |
| September 09, 2026 | 355.71M |
| September 08, 2026 | 355.60M |
| September 04, 2026 | 356.10M |
| September 03, 2026 | 356.53M |
| September 02, 2026 | 355.68M |
| September 01, 2026 | 353.34M |
| August 31, 2026 | 356.97M |
| August 28, 2026 | 389.40M |
| August 27, 2026 | 371.94M |
| August 26, 2026 | 361.69M |
| August 25, 2026 | 363.19M |
| August 24, 2026 | 360.82M |
| August 21, 2026 | 356.01M |
| August 20, 2026 | 358.78M |
| August 19, 2026 | 369.28M |
| August 18, 2026 | 373.21M |
| August 17, 2026 | 377.55M |
| August 14, 2026 | 393.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.514B |
| Alnylam Pharmaceuticals, Inc. | 29.64B |
| Anika Therapeutics, Inc. | 273.50M |
| Savara, Inc. | 724.16M |
| Vericel Corp. | 2.108B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.221M |
| Revenue (Quarterly) | 0.807M |
| Total Expenses (Quarterly) | 10.03M |
| EPS Diluted (Quarterly) | -0.0058 |
| Gross Profit Margin (Quarterly) | -5.58% |
| Profit Margin (Quarterly) | -1.14K% |
| Earnings Yield | -16.74% |
| Normalized Earnings Yield | -23.47 |